Proprietary Lateral CAR Platform achieved pre-clinical proof-of-concept data demonstrating prolonged disease-free survival compared to other CAR T-cell products. Lead programme, LEU011 has completed pre-clinical development for the treatment of solid tumours and is in pre-clinical development for a range of haematological malignancies. Leucid expects to file its CTA to initiate the clinical trial in H1 […]
Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies Single-target license with upfront and milestone payments plus royalties First Synaffix partnership announced with a Korean company Read more…
Scientific milestones achieved significantly ahead of schedule Cambridge, UK, 19 January 2023 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the completion of its £21.5m (US $28.5m) Series B financing, with a £6m (US $7.5m) financing extension. The syndicate comprised its Series B subscribing investors including CRT Pioneer Fund, Claris Ventures, 2Invest, […]
Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications Key Highlights · Newly filed patent application to protect use of POLB 001 for new oncology indication · Scientific findings indicate POLB 001 has the potential to dampen the pro-inflammatory […]
Matthew Fyfe joins as Senior Vice President of Therapeutics Beth Thomas promoted to Vice President of Medicinal Chemistry 10 January 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announces the appointment of Matthew Fyfe […]
